Licofelone--a novel analgesic and anti-inflammatory agent.

Author: KulkarniS K, SinghVijay Pal

Paper Details 
Original Abstract of the Article :
Dual inhibitors that block both cyclooxygenase (COX) and lipoxygenase (LOX) metabolic pathways of arachidonic acid are expected to possess clinical advantages over the selective inhibitors of COX enzyme. One of the most promising compounds belonging to this category is licofelone ([2,2 -dimethyl -6-...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.2174/156802607779941305

データ提供:米国国立医学図書館(NLM)

Licofelone: A New Oasis in the Desert of Pain

Pain management research continuously seeks novel and effective analgesics with fewer side effects. This review examines the pharmacological profile of licofelone, a dual inhibitor of both cyclooxygenase (COX) and lipoxygenase (LOX) pathways of arachidonic acid metabolism. The authors highlight the potential advantages of dual inhibitors over selective COX inhibitors, particularly in terms of reducing gastrointestinal (GI) side effects. Preclinical studies have demonstrated licofelone’s analgesic, anti-inflammatory, and antiasthmatic effects in various animal models, with a favorable safety profile.

A New Path in the Sands: Dual Inhibition for Pain Relief

The study's exploration of licofelone's potential as a dual inhibitor opens up new possibilities for pain management.

Navigating the Desert of Pain

As a pain management specialist, I am constantly searching for safe and effective treatments for my patients. This review highlights the potential of licofelone as a dual inhibitor, offering a promising new avenue for pain management with a potentially reduced risk of GI side effects.

Dr. Camel's Conclusion

This review examines the pharmacological profile of licofelone, a dual inhibitor of both cyclooxygenase (COX) and lipoxygenase (LOX) pathways of arachidonic acid metabolism. The authors highlight the potential advantages of dual inhibitors over selective COX inhibitors, particularly in terms of reducing gastrointestinal (GI) side effects. Preclinical studies have demonstrated licofelone’s analgesic, anti-inflammatory, and antiasthmatic effects in various animal models, with a favorable safety profile.

Date :
  1. Date Completed 2007-03-26
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

17305568

DOI: Digital Object Identifier

10.2174/156802607779941305

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.